It is time for a state to challenge the 1984 National Organ Transplant Act and offer funeral benefits or some other reward to the estate of those who will give their organs at death.

Facebook Inc. took a momentous action last week. And I don’t mean its announced intention to sell shares for $28 to $35 in an initial public offering later this month.

Why are so many investors boors?

I’m not talking about a couple of bad eggs here or there.  As far as I can tell, there’s a distinctive phenotype that may not describe all investors, but certainly seems to capture far more than chance alone would dictate.

Boors, you ask? ...

What should we make of Arizona's new law for rationing organ transplants?

"Phake: The Deadly World of Falsified and Substandard Medicines" explores the underground trade in illegal medicines that kills over 100,000 people per year and supplants billions of dollars of real products.

Did Steve Jobs' wealth buy him a faster liver transplant? It certainly helped--and the Apple CEO's odyssey showcases some of the problems with organ donations in America.

In October of 2009, Kumud Majumder, the father of an 11-year-old son with advanced leukemia, joined a lawsuit challenging the federal ban on compensating bone-marrow donors. He wanted to save his son's life. Last week Mr. Majumder and his co-plaintiffs enjoyed a victory. The U.S. Court of Appeals for the Ninth Circuit ruled that the majority of bone-marrow donors may lawfully be compensated.

Please note: This event has been canceled. At this event, Sally Satel, M.D., will discuss her new book, When Altruism Isn’t Enough: The Case for Compensating Kidney Donors and the national organ shortage.